

ANNUAL REPORT 2023



Arthritis Foundation of WA Incorporated
Wyllie Arthritis Centre 17 Lemnos Street, Shenton Park, WA 6008
PO Box 34, Wembley, WA 6913
Phone: 1800 011 041 | ABN: 43 390 598 024

www.arthritiswa.org.au





JOINT PATRONS

His Excellency The Honourable Christopher John Dawson AC APM
Governor of Western Australia
and **Mrs Darrilyn Dawson**

LIFE GOVERNORS

Dr Jack Edelman AM MBBS FRACP
Dr Paul Zilko FRACP FRCPA
Mr Ron J Elphick

GOVERNORS

Mr Pat Doody
Mr Mal Atwell
Prof Richard Prince BSc MB ChB Birm, MD Melb, FRACP, MRCP (UK)
Ms Deborah Borshoff BA (UWA) Dip Ed
Ms Jean McQuade
Mrs Cecilia Chivers
Dr Bob Langlands

BOARD

President

Dr Jack Edelman AM MBBS FRACP

Vice President

Dr Irene D Froyland PhD (Crim), MA (Psych), Dip Ed

Hon Treasurer

Dr Silvia Caratti PhD B.Com CTA FCA MBA

Secretary

Mr Brad Gordon SA (Fin), Fdn DFP, MAICD SMSF Specialist Advisor™

Members

Dr Charles Inderjeeth MB ChB, MPH, NHMRC-NCIS Fellow, FRACP
Dr Joe Kosterich MBBS
Ms Anita Clayton (Consumer Representative)
Mr Bill Cox

STAFF

Executive Director

Manager - Health, Education & Research Programs

Health Services Officer

Health Services Coordinator

Health Services Education Coordinator

Exercise Instructor

Program Coordinator Children & Young People's Services

Volunteer Coordinator

Business Manager

Accounts & Administration Officer

Reception/Accounts

Reception/Administration Assistant

Manager - Public Relations, Marketing & Communications

Marketing & Communications Officer

Digital Marketing Officer

Manager - Community Relations

Donor Support Officer

Ric Forlano

Jennifer Persaud (resigned in July)

David Smith (commenced in September)

Clara Connor

Reetika Chaudhary

Nicolas Gallardo

Kaz Ventouras

Lisa Henry

Debora Brown

Julie Liddell

Alana Brown

Ann Whyte

Linda McLean

Lily Lomma

Katrina Benson

Karina Hilton

Sue Wilkinson

Ashwini Tak

TABLE OF CONTENTS

5	President's Report
7	Treasurer's Report
8	Performance Highlights
10	Health Service Programs Delivered
18	Projects and Grants
20	Research
24	AJ Smith Society
25	Publications
26	Financial Management



History

The Western Australian Arthritis & Rheumatism Foundation (WAARF) was inaugurated in October 1972, as a non-government organisation, through the efforts of Drs Phyllis Goatcher, Evan Owen and Roger Dawkins. In 1991, the organisation's name was updated and changed to its present form.

Mission

Our Objective is to reduce the incidence and disabling effects of arthritis and osteoporosis, and related conditions in the people of WA.

Vision

AOWA will educate and assist people with musculoskeletal conditions by being a pre-eminent point of referral. With sustainable funding, provide professional partnerships to establish improved health services in Western Australia whilst always supporting promising research.

Values

- **Compassion:** We demonstrate kindness and care towards each individual we interact with.
- **Advocate:** We stand up and support those who are dealing with bone and joint conditions.
- **Responsibility:** We take ownership of our communication, behaviour, and outcomes.
- **Respect:** We treat people with respect and professionalism, valuing their dignity.
- **Integrity:** We uphold ethical principles and build trust through honesty and responsible behaviour.
- **Collaboration:** We work together to achieve greater success.

PRESIDENT'S REPORT

Dr Jack Edelman AM MBBS FRACP



It gives me great pleasure to present Arthritis & Osteoporosis WA's (AOWA) annual report for the year 2023. Through our dedication and collaborative efforts, we have continued to make significant strides in improving the lives of individuals affected by arthritis and related conditions across our communities.

In 2023, AOWA made substantial progress in various areas, including rural health, education for health professionals, consumer assistance, exercise programs, and initiatives focused on young people living with arthritis.

Our **Rural Rheumatology Clinic Service**, a cornerstone of our rural health initiatives, has been instrumental in delivering vital rheumatology services to remote areas since 1974. In 2023, we facilitated 20 clinics in the Goldfields and four in Esperance, providing essential care to those in need.

Education remains a key focus, with AOWA delivering five educational sessions to 60 **health professionals**, covering topics such as medicinal cannabis, chronic pain management, and osteoporosis.

We are committed to empowering individuals with arthritis and related conditions to actively manage their health. Through our **self-management programs**, the Arthritis Keys Programs, we provided valuable education and support to 92 people across six locations in 2023.

Our outreach efforts extended to **public seminars, community speakers, support groups, and telephone services**, reaching hundreds of individuals seeking information and support for musculoskeletal conditions.

Exercise programs have been pivotal in promoting physical wellbeing, with a notable growth in attendance in both land-based and hydrotherapy classes. In 2023, we saw an 8.6% increase in hydrotherapy attendance and a remarkable 33.7% increase in land-based class attendance.

Our commitment to young people living with arthritis was evident through initiatives such as the **Healthy Bones & Joints Land-Based Exercise Program, Hydrotherapy Classes, The Arthritis Getaway**, and our **Arthritis Kids Camp**, providing invaluable support and resources tailored to their unique needs.

None of these achievements would have been possible without the dedication of our volunteers, whose unwavering support and commitment have been integral to the success of our programs and services.

Additionally, our involvement in health projects demonstrates our dedication to advancing research, education, and resources in the field of musculoskeletal health. Last year the **Staying Moving, Staying Strong project** developed culturally sensitive resources for Aboriginal Australians living with arthritis; the **ATLAS project** is developing an online arthritis education platform for health professionals with a specific emphasis on building knowledge and skills for direct application to clinical practice; and the **Skeletal Central project** is creating an online game integrated with immersive educational resources to teach school-aged children good bone health.

As we reflect on the past year's accomplishments, I extend my deepest gratitude to our board members, staff, volunteers, and supporters for their tireless efforts and unwavering commitment to the mission of AOWA. Together, we will continue to make a meaningful difference in the lives of individuals affected by musculoskeletal disorders throughout Western Australia.



TREASURER'S REPORT

Dr Silvia Caratti PhD B.Com CTA FCA MBA



Despite challenging times with increases in the cost of living putting pressure on donations, I am pleased to report that our diversified income stream has meant that we were still able to support our members through increased spending on Arthritis research, education and community support funding. Whilst there was a small operating deficit of \$47,926 for the year, our reserves have meant that we were able to continue to provide our services sustainably.

We continue to monitor costs closely, and I'm pleased to inform that we were able to keep our administration expenses down to 6% of total income.


Our research contribution increased from \$94,549 to \$200,294 during the year, and we saw an increase in the amount spent on education, health services, and community support programs. All while maintaining our administration expenses at 6% of our revenue.

We are required to record our investments at fair value and our portfolio, and at the end of 2022/2023, the market reversed many of the losses of the prior year to provide an increase in fair value of \$881,145 for the year. Our investment portfolio continues to contribute to our operations by providing \$442,685 in earnings to provide services to our members.


Overall, while there has been some pressure on fundraising, our organisation remains in a strong financial position, with a solid asset base providing a platform that will enable us to continue prioritising innovative programs and vital research for those with arthritis-related and bone and joint diseases.

Our sound financial position is the result of the commitment of the Finance Committee and Board of Management, who give their time freely, not forgetting the staff and many volunteers who support the foundation. I wish to thank all those involved who contribute to the financial success of our organisation. It is through their efforts that we are well-placed for the future.

REVENUE 2023



EXPENDITURE 2023



PERFORMANCE HIGHLIGHTS



Education for Health Professionals

AOWA delivered **five online educational sessions to 60 health professionals** about the following topics:

- Medicinal Cannabis: A Crash Course What You Need to Know
- Understanding and Managing Chronic Pain
- Osteoporosis: Epidemiology, Risk, Prevention, Identification & Treatment
- Osteoporosis: Pharmacological Management
- Clinical Update: Rheumatic Disease Masqueraders in Back Pain (Hybrid)



Public Seminars/ Talks/ Community Speakers

AOWA delivered **11 public seminars/talks in metro and rural areas attended by 145 consumers, and community speakers visited 23 community groups, reaching 542 people.**



Support Groups

Six disease-specific support groups provided a safe space for individuals with musculoskeletal conditions to connect, share lived experiences, and receive peer support. These support groups held **54 meetings and assisted 351 individuals.**



Land-based Exercise Classes

Provided **exercise classes across three venues, with 4,093 attendances.** Classes included exercises for Arthritis and Osteoporosis, Gentle and Chair Yoga, Tai Chi, and classes for children with Chronic Musculoskeletal Conditions.



Hydrotherapy Classes

AOWA provided hydrotherapy classes for individuals living with musculoskeletal conditions at our Shenton Park and Albany locations. **1,557 warm water exercise sessions attracted over 12,600 attendees.**



Self Management Programs

AOWA delivered **13 self-management programs to 92 people across six locations, plus one online program.** The programs are designed for people with Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.



HEALTH SERVICE PROGRAMS DELIVERED



Arthritis & Osteoporosis WA (AOWA) provide a comprehensive range of services and programs to support the management of musculoskeletal disorders for all West Australians.

Rural Health

Rural Rheumatology Clinics


The Rural Rheumatology Clinic Service has been delivering rheumatology services to rural and remote areas of WA since 1974. These clinics enable visiting rheumatologists to provide a much-needed lifeline to support consumers with chronic musculoskeletal conditions living in rural areas.

AOWA assist with administering the clinic program in the Goldfields and Esperance.

In 2023, 20 and 4 clinics were arranged in the Goldfields and Esperance, respectively, delivered by 6 Rheumatologists.

AOWA also prepares a consolidated schedule of state-wide clinics to support the service.

Albany	Clinic held monthly	Kalgoorlie	Clinic held monthly
Broome	Clinic held six times a year	Karratha	Clinic held seven times a year
Derby	Clinic held five times a year	Kununurra	Clinic held five times a year
Esperance	Clinic held six times a year	Port Hedland	Clinic held twice a year
Geraldton	Clinic held nine times a year	Bunbury & Dunsborough	Private clinics



Building Workforce Capacity

Education for Health Professionals

It is important that the health workforce are aware of and informed about musculoskeletal conditions.

AOWA works with health professionals to provide them with up-to-date musculoskeletal education. The objective is to achieve a successful transfer of knowledge to health professionals in order that it may be applied in clinical interactions and management of arthritis and related conditions.

In 2023, AOWA delivered five educational sessions to 60 health professionals:

- Medicinal Cannabis: A Crash Course What You Need to Know (Online)
- Understanding and Managing Chronic Pain (Online)
- Osteoporosis: Epidemiology, Risk, Prevention, Identification & Treatment (Online)
- Osteoporosis: Pharmacological Management (Online)
- Clinical Update: Rheumatic Disease Masqueraders in Back Pain (Hybrid)

HEALTH SERVICE PROGRAMS DELIVERED



Assisting Consumers

AOWA is committed to enabling people with arthritis and related conditions to become informed about their condition. This is achieved through the provision of education to assist people living with arthritis to actively participate in the management of their health.

Self Management Programs

AOWA have been delivering self-management programs (SMPs) for over 20 years. These programs, named '*Arthritis Keys Programs*', aim to empower consumers with the knowledge and skills to manage their arthritis in partnership with their health professional team.

AOWA have a highly skilled team of seven facilitators, who in 2023, delivered a total of 13 self-management programs to 92 people across six locations, plus one online program. The programs are designed for people living with:

- Osteoarthritis
- Rheumatoid Arthritis
- Ankylosing Spondylitis and Psoriatic Arthritis

Public Seminars/Talks

Public seminars/talks are standalone education events organised by AOWA and open to all consumers. The events aim to provide high-quality arthritis and musculoskeletal education delivered by well-credentialed presenters.

In 2023, AOWA delivered 11 public seminars/talks in metro and rural areas that were attended by 145 consumers.

Community Speakers

Trained AOWA volunteers visit specific, closed community groups around the Perth metro area to deliver education about arthritis and osteoporosis.

In 2023, AOWA community speakers visited 23 community groups, reaching 542 people.

Support Groups

Support Groups bring people together with chronic musculoskeletal conditions to share lived experiences and provide peer support in a safe environment. Six disease-specific support groups ran in 2023, with a total of 54 meetings and 351 attendances.

Telephone Services

AOWA provide a credible telephone advice and support service for consumers. Run by volunteers and staff, the service responds to enquiries and requests for information about musculoskeletal conditions.

In 2023, AOWA telephone advisors and staff responded to 326 phone calls, 52 'walk-ins' and 44 email requests from consumers for information about musculoskeletal conditions.

Volunteers

Volunteers have been involved with AOWA since its inception in 1972 and we are very fortunate to have a loyal band of volunteers.

Volunteers assist across a range of roles and activities, including AOWA Board positions, community speaking, leading support groups, assisting with office work, attending camps for children and young adults and providing telephone advice and support.

Volunteers are essential to allow AOWA to continue to deliver our high-quality services. AOWA currently has 58 active volunteers.

The Board and staff are grateful for all their support.



HEALTH SERVICE PROGRAMS DELIVERED



Exercise Programs

AOWA provides a diverse range of land-based and hydrotherapy exercise programs for consumers with musculoskeletal conditions. Led by Health Professionals and Exercise Instructors, the classes are provided at a relatively low cost to facilitate access to consumers.

These programs, both hydrotherapy and land-based, continue to grow strongly, reflecting the value of exercise to persons living with musculoskeletal conditions. In 2023, we saw an 8.6% and 33.7% growth in hydrotherapy and land-based attendance, respectively.

Land-Based Exercise Classes

In 2023, land-based classes were provided across three venues with 4,093 attendances. Classes are offered from beginner through to advanced levels and include the following:

- Land-based exercise classes for arthritis
- Land-based exercise classes for osteoporosis,
- Beginner, gentle, and chair yoga classes for arthritis,
- Tai Chi for arthritis, and
- Land-based exercises classes for children living with chronic musculoskeletal conditions.

Hydrotherapy Classes

In 2023, 1,557 warm water exercise sessions were conducted, with a total attendance of 12,645. These sessions include:

- Higher-intensity Aqua Fitness classes,
- Lower-intensity Gentle Movers classes
- Instructor-led Guided Open Water sessions, and
- Land and water classes for people with Ankylosing Spondylitis.
- Classes for children living with chronic musculoskeletal conditions.

Online Exercise Classes

AOWA ran online classes until September 2023 before they were discontinued due to instructor availability and low participant numbers.



YOUNG PEOPLE LIVING WITH ARTHRITIS



Healthy Bones & Joints Land-Based Exercise Program

The Healthy Bones & Joints program, run by Western Kids Health, is a land-based bone and joint education and exercise program for teenagers living with chronic musculoskeletal conditions.

The program is led by a Physiotherapist with experience in paediatric health and is designed for young people aged 11 (or year 6) to 17.

Hydrotherapy Classes for Young People

AOWA provides support to children living with JIA and chronic musculoskeletal conditions through the delivery of hydrotherapy classes. A Physiotherapist leads the program with experience in paediatric health. Classes run every Monday for eight weeks during the school term and are designed to provide a tailored exercise program in a fun and supportive environment.

The Arthritis Getaway (TAG)

The Arthritis Getaway is an annual weekend getaway designed to educate and support young adults with chronic rheumatic conditions. The event is designed to enable young people aged 18 to 35 who are living with arthritis to meet and support one another and learn about managing arthritis as they advance through their adulthood years.

In 2023, 18 young people participated in TAG, which was held in Dunsborough.

Camps

AOWA has organised an annual camp for children with musculoskeletal conditions for over 30 years. The camp offers children the opportunity to participate in activities and education that cater to their condition and foster empowerment, peer support, and self-management.

An established and regular event in the AOWA calendar, this camp consistently rates as a favourite event with participants. In September 2023, 60 children participated in the camp held at Forest Edge, Waroona.

AOWA camps are supported by an excellent team of volunteers who give a week of their time to attend camp. Volunteers engage in training to help prepare them to deliver a safe and high-quality camp experience.

The camp would not be possible without the wonderful support from Lotterywest and the Richard Lockwood Foundation.



PROJECTS & GRANTS



AOWA actively seeks grant funding to support work that benefits people with arthritis and related conditions.

In 2023, AOWA engaged in work to support several projects as follows:

Skeletal Central

AOWA and Edith Cowan University are nearing completion of immersive digital educational resources (predominantly a computer game) for teachers and students to increase their understanding of bone and joint disease and strengthen their knowledge about the musculoskeletal system.

The game aims to support learning and behaviour change to optimise bone health, prevent disease, reduce childhood fractures, and build optimal skeletal structures to reduce fracture rates in later life.

ATLAS

In 2019, acting as the lead agency, Arthritis Australia brought together a consortium of member groups (including AOWA), to create an arthritis education platform – primarily an eLearning resource delivered using an internationally available Learning Management System.

The e-Learning program, named ATLAS (Arthritis Training, Learning and up-Skilling), focuses on delivering osteoarthritis (OA) and rheumatoid arthritis (RA) education for health professionals with a specific emphasis on building knowledge and skills for direct application to clinical practice. 2023 saw the bulk of the content development and the project is due to launch in 2024 where it will be accessible online to a health professional audience in Australia, and beyond.





The subject matter has been developed by a team of Australian and international content experts and has been through a process of expert peer review. All content is supported by learning objectives and outcomes and will be delivered in a flexible, modular format to suit different learning styles and preferences.

Staying Moving, Staying Strong (SMSS)

Funded by the Australian Commonwealth Government via a grant administered by Arthritis Australia, the SMSS project aimed to develop culturally sensitive resources for Aboriginal Australians living with arthritis.

In November 2023, these resources were launched and distributed extensively across Australia. The resources are now available in print, via internet download, and in video viewable format. Articles have been published in 4 journals to date, highlighting the work that went into designing and developing the resources.

AOWA partnered with the National Aboriginal Community Controlled Health Organisation, the University of Melbourne, the University of Western Australia, and Curtin University to deliver the project. The project included extensive interviews with Aboriginal people living with musculoskeletal conditions across WA and Victoria.



[ARTHRTISAUSTRALIA.COM.AU/STAYING-MOVING-STAYING-STRONG](https://arthritisaustralia.com.au/staying-moving-staying-strong) 

RESEARCH



Our commitment to research continues under the direction of Professor Hans Nossent as Chair of Rheumatology and Musculoskeletal Medicine at UWA.

In the medical field, continued education and service play a critical role in ensuring a healthy and informed population. This report focuses on the need for increased training opportunities in Rheumatology to bridge the gap between service provision and requirements in the field. The report also highlights the contributions of Professor Nossent to the medical community through his research, service, and postgraduate supervision.

Prof. Nossent's research has continued to progress well, with several studies being published in scientific journals and presented at conferences. Overall, this report underscores the importance of investing in research and training opportunities to improve the health outcomes of patients with rheumatic diseases.

Service

Prof. Nossent remained an Advisory Board member to Lupus WA, which has now become a full subsidiary group under AOFWA, and provided oral and written presentations for the Arthritis Foundation.

Prof Nossent serves on the Expert Advisory Group Expert Advisory Group (EAG) for the Rheumatoid Arthritis e-learning Project, which is developing a modular-based, digital arthritis learning platform for health professionals that will be accessible to users at (inter-) national level.

Departmental duties at SCGH continue to include clinics/ward rounds and trainee and medical student supervision; he provided four full-day rural clinics in Kalgoorlie and was a reviewer for papers submitted to a range of scientific journals.

Teaching

The now well-established one-week teaching block in the second year of the Doctor of Medicine course at UWA. "Rheumatology Week" continues to be well received by the medical students. In this weeklong exposure, Rheumatologist at the three public hospitals teach MD year 2 students about the various rheumatic diseases encountered during ward rounds and at least three clinic visits, how to examine joints and how to interpret these and additional findings from blood tests and imaging modalities.

A refresher Rheumatology seminar in the last (4th) year of the MD study at UWA has been added to the curriculum. While students would welcome more Rheumatology teaching, limited resources in public hospitals unfortunately do not allow this. Nonetheless, the current teaching setup continues to be a good pathway for recruiting young doctors to Rheumatology specialist training in WA.

Supervision of advanced trainees and basic physicians at SCGH Rheumatology continued in 2023 as before, but such training opportunities in Rheumatology continue to fall behind requirements. With a changing workforce and increased demand for rheumatology consultations, the lack of Rheumatologists in WA is increasingly felt. Fewer specialists in the coming years with increasing demand clearly indicate that more training opportunities are needed, although this requires complex dealings with WA Health and RACP. The recent ARA and WA Health workforce surveys, however, have clearly illustrated the increasing gap between service demand and provision in Rheumatology, not only in WA but nationwide.

The AOFWA support for a postdoc position (Dr Khalid Almutairi) has resulted in recruiting three medical students who will complete scholarly research within the field of Rheumatoid Arthritis in the next two years. Postgraduate supervision began in 2023 for another PhD student (Dr Owen-Williams) in the field of Rheumatoid Arthritis, while a private practising Rheumatologist (Dr Ai Tran) successfully completed his Master thesis on the efficacy of Covid-19 vaccinations in arthritis patients.

Research Activities

The established lines of clinic-epidemiological research are progressing well. In 2023, this included a sabbatical period visit to Karolinska Hospital in Sweden, which offered much to learn for WA. This includes how a fully funded public hospital is able to provide all necessary and specialised care in Rheumatology to 2.2 million inhabitants of metropolitan Stockholm. In addition, it provided a view of what a truly paperless hospital should be like with digital communication within the hospitals as well as with GPs, pharmacies and other hospitals, ensuring the timely and correct spreading of information.

Abstracts of research work published in 2023 are given below for interested readers.

1. Mortality Trends Among Patients with Rheumatoid Arthritis in Western Australia

With scarce comparative data on mortality in Australian patients with rheumatoid arthritis (RA), we investigated temporal changes in standardized mortality rates for patients with RA using longitudinal linked population-wide health data in Western Australia (WA) over the period 1980 to 2015.

2. Systemic juvenile idiopathic arthritis: frequency and long-term outcome in WA

Systemic juvenile idiopathic arthritis (S-JIA) is a rare but potentially life threatening autoinflammatory condition of childhood. Given the limited data on S-JIA from the Australasian region, we investigated the epidemiological characteristics and long-term disease outcome in S-JIA. All hospitalised patients under the age of 16 years registered with ICD-10-AM code M08.2 in the period 1999-2014 were identified in longitudinally linked administrative health data across all Western Australian (WA) hospitals.

3. Protein-losing enteropathy as a rare manifestation of systemic lupus erythematosus

4. Joint surgery rates in lupus: a long-term cohort study

With scarce data on the need and type of joint surgery in SLE, we investigated the long-term rates and underlying causes for arthroplasty, arthrodesis and synovectomy in patients with SLE.

5. The effect of TNF treatment uptake on incident hospital admission in Western Australia

Treatment strategies for juvenile idiopathic arthritis (JIA) have shifted significantly over the last 20 years. We examined the effect of the introduction of government-subsidised TNF inhibitor (TNFi) treatment on incident hospitalisation for JIA.

6. Cancer development in patients hospitalized with systemic lupus erythematosus: A population-level data linkage study

To explore the association between systemic lupus erythematosus (SLE) with the risk of cancer development and subsequent 5-year mortality in Western Australia (WA).

7. Trends in Hospitalization for Tuberculosis and Other Opportunistic Infections in Australian Patients with Inflammatory Joint Diseases

As immune-modulating therapy has become the standard of care for idiopathic inflammatory joint diseases (IJD), we investigated whether this has changed the rates for hospitalization with opportunistic infections (OI).

8. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

The persistence of immunogenicity in patients with immune-mediated inflammatory diseases (IMID) on disease-modifying antirheumatic therapy (DMARD) has been less well studied. This extension study evaluates the SARS-CoV2 antibody decay kinetics 6 months following two doses of ChAdOx1nCov-19 (AZ) and BNT162b (Pfizer) and subsequent response following an mRNA booster.

9. Risk of Major Adverse Cardiovascular Event Following Incident Hospitalization for Acute Gout: A Western Australian Population-Level Linked Data Study

Cardiovascular disease is the most common cause of death in people with gout. Acute inflammation, which is a characteristic of gout, may have a mechanistic role in major adverse cardiovascular events (MACEs). We aimed to examine the relationship between admissions to a hospital with acute gout and MACEs in a large population-based data set.

10. Cancer Risk and Mortality in Hospitalized Patients With Idiopathic Inflammatory Myopathies in Western Australia

To compare cancer incidence, type, and survival between patients with idiopathic inflammatory myopathies (IIMs) in Western Australia (WA) and the general population.

11. Population-wide long-term study of incidence, renal failure, and mortality rates for lupus nephritis

Given limited regional data, we investigate the state-wide epidemiology, renal and patient outcomes for lupus nephritis (LN) in Western Australia (WA).

12. The spectrum of idiopathic inflammatory myopathies in Western Australia: epidemiological characteristics and mortality over time

To determine long-term overall and subgroup-specific incidence rates and associated mortality for idiopathic inflammatory myopathies (IIM) in a population-wide study.

Scientific Papers Published in 2023

(all papers acknowledge the support provided by AOWA)

Almutairi, K. B., Inderjeeth, C. A., Preen, D. B., Keen, H. I., & Nossent, J. C. (2023). Mortality Trends Among Patients with Rheumatoid Arthritis in Western Australia. *Rheumatology and therapy*, 10(4), 1021–1037.

<https://doi.org/10.1007/s40744-023-00562-0>

Nossent, J. C., Kelty, E., Keen, H., Preen, D., & Inderjeeth, C. (2023). Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia. *Rheumatology International*, 43(7), 1357–1362.

<https://doi.org/10.1007/s00296-023-05318-1>

Ng, D. M., Sek, K., & Nossent, J. (2023). Protein-losing enteropathy as a rare manifestation of systemic lupus erythematosus. *BMJ case reports*, 16(8), e256680.

<https://doi.org/10.1136/bcr-2023-256680>

Nossent, J., Keen, H. I., Preen, D. B., & Inderjeeth, C. A. (2024). Joint surgery rates in lupus: a long-term cohort study. *Lupus science & medicine*, 11(1), e001045. <https://doi.org/10.1136/lupus-2023-001045>

Kelty, E., Quintrell, E., Preen, D. B., Manners, P., & Nossent, J. (2023). The effect of TNF treatment uptake on incident hospital admission in Western Australia. *Pediatric rheumatology online journal*, 21(1), 29. <https://doi.org/10.1186/s12969-023-00810-1>

Raymond, W. D., Preen, D. B., Keen, H. I., Inderjeeth, C. A., & Nossent, J. C. (2023). Cancer development in patients hospitalized with systemic lupus erythematosus: A population-level data linkage study. *International journal of rheumatic diseases*, 26(8), 1557–1570.

<https://doi.org/10.1111/1756-185X.14784>

Nossent, J. C., Keen, H. I., Preen, D. B., & Inderjeeth, C. A. (2023). Trends in Hospitalization for Tuberculosis and Other Opportunistic Infections in Australian Patients with Inflammatory Joint Diseases. *Rheumatology and therapy*, 10(3), 563–573.

<https://doi.org/10.1007/s40744-023-00534-4>

Tran, A. P., Tassone, D. F., Ding, N. S., & Nossent, J. (2023). Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). *RMD open*, 9(1), e002871. <https://doi.org/10.1136/rmdopen-2022-002871>

Lopez, D., Dwivedi, G., Nossent, J., Preen, D. B., Murray, K., Raymond, W., Inderjeeth, C., & Keen, H. I. (2023). Risk of Major Adverse Cardiovascular Event Following Incident Hospitalization for Acute Gout: A Western Australian Population-Level Linked Data Study. *ACR open rheumatology*, 5(6), 298–304. <https://doi.org/10.1002/acr2.11540>

Nossent, J. C., Keen, H., Preen, D., & Inderjeeth, C. (2024). Cancer Risk and Mortality in Hospitalized Patients With Idiopathic Inflammatory Myopathies in Western Australia. *The Journal of rheumatology*, 51(4), 396–402.

<https://doi.org/10.3899/jrheum.2023-1044>

Nossent, J. C., Keen, H. I., Preen, D. B., & Inderjeeth, C. A. (2024). Population-wide long-term study of incidence, renal failure, and mortality rates for lupus nephritis. *International journal of rheumatic diseases*, 27(2), e15079.

<https://doi.org/10.1111/1756-185X.15079>

Nossent, J., Keen, H., Preen, D. B., & Inderjeeth, C. A. (2024). The spectrum of idiopathic inflammatory myopathies in Western Australia: epidemiological characteristics and mortality over time. *Rheumatology international*, 44(2), 329–337.

<https://doi.org/10.1007/s00296-023-05475-3>



AJ SMITH SOCIETY

For more information, visit

www.arthritiswa.org.au or call 1800 011 041



...the wisdom of writing a Will!

Failing to write a Will is a bit like leaving home without locking the door. You just don't do it. And yet, in a room filled with older people, about half have not written a Will. You might guess the level of interest shown by the rest.

A Will is an important document. It tells others how you want your assets to be shared on your death. Everything you have acquired over your lifetime, your house and investments, needs to be passed on to someone or charity or friend.

If you have no Will, the government must appoint an Executor who will do the job you should have done and share your assets among the family as the rules allow.

That means friends or charities, not being a blood-related family member, get nothing unless you name the friend or charity in your Will. Let me say it again...

It is therefore important YOU write your Will because no one else can possibly know how you want your assets to be shared – only YOU can decide.

It's also nice if you decide what to do with those 'little' things that may have no value but are reminders of happier times. To return a brooch to a favourite niece or direct that a much-used tea set might go to the cleaning lady because she loves it so – will create happy memories because you 'passed such gifts on'.

... but your work is only half done until you write it all down.

Which is why **we developed our Personal Record Book** in which you can record details of bank accounts, insurance policies, names of your broker, accountant, solicitors, where important papers are held and who holds your Will.

If you would like your free copy, please contact us on (08) 9388 2199.


Of course, we also hope you will include a gift to the Arthritis Foundation of WA in your Will too. Such gifts are called bequests, which we use to research a cure for arthritis, to help ease the pain, and to make a difference in lives neither of us will ever see.

Should you agree, please write it in your Will...

Whilst there is no obligation to do so, letting us know you have, or are thinking of leaving a bequest to Arthritis & Osteoporosis WA will greatly assist us with our planning. It will also give us the opportunity to say thank you and keep you up to date with our work and future bequest events.

All bequests to Arthritis & Osteoporosis WA are treated in a confidential matter. For further information or for a confidential chat, please call us on (08) 9388 2199.

PUBLICATIONS



AOWA endeavours to provide high-quality publications and educational resources to inform those living with musculoskeletal conditions.

Arthritis Today Magazine

A high-quality magazine with a circulation of 10,000 per issue. This 36-page magazine is published three times per year and delivered to subscribers, health professionals, medical centres and community organisations. It includes articles from local health professionals, the latest research news, information on diet, nutrition, medications and treatments, consumer health programs and support services, seminars and special events.

Arthritis- eNews

A monthly digital newsletter informs over 9,000 subscribers of the latest research news, clinical trials, consumer health programs and services, free consumer resources, seminars, talks, and special events.

Information Booklets and Fact Sheets

Our printed resources are accessible to the community and cover most of the 100+ bone and joint disease types. We also provide multicultural information fact sheets in Arabic, Chinese, Croatian, Greek, Italian, Korean, Macedonian, Persian, Spanish and Vietnamese.

Promotional Campaigns

A range of health campaigns for bone and joint disease were promoted and disseminated through printed and digital media.

Social Media

AOWA has a presence on several social media platforms, including LinkedIn, Twitter, YouTube, Instagram, and Facebook, and an engaging community of over 10,000 followers.

Website

Our website provides an overview of our health programs and services. It is a valuable information resource that includes articles written by local and national health professionals, videos, podcasts, downloadable content, and personal stories from people living with musculoskeletal conditions.

FINANCIAL MANAGEMENT



ARTHRITIS FOUNDATION OF W.A. INCORPORATED

ABN 43 390 598 024

Financial Report

For the year ended 31 December 2023

C O N T E N T S

Statement by the Board of Management	1
Auditor's Independence Declaration	2
Independent Auditors' Report	3
Statement of Comprehensive Income	6
Statement of Financial Position	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

STATEMENT BY THE BOARD OF MANAGEMENT

In the opinion of the Board of Management of the Arthritis Foundation of W.A. Incorporated ("the Foundation"):

- (i) The attached financial statements and notes give a true and fair view of the Foundation as at 31 December 2023 and of its performance for the financial year ended on that date;
- (ii) The attached financial statements and notes comply with the Accounting Standards, the *Associations Incorporations Act 2015*, the *Australian Charities and Australian Not-for-profits Commission Act 2012* and the *Charitable Collections Act 1946 (WA)* and associated regulations;
- (iii) The attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board;
- (iv) The operations of the Foundation have been carried out in accordance with the Constitution of the Foundation; and
- (v) There are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Board of Management by:



President



Board Member

Dated: 12 April 2024
Perth, Western Australia

AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the audit of the financial report of Arthritis Foundation of W.A. Incorporated for the year ended 31 December 2023, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- a) the auditor independence requirements of the *Associations Incorporation Act 2015 (WA)* and *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- b) any applicable code of professional conduct in relation to the audit.



Perth, Western Australia
12 April 2024

L Di Giallonardo
Partner

hl**b.com.au**

HLB Mann Judd (WA Partnership) ABN 22 193 232 714

Level 4, 130 Stirling Street, Perth WA 6000 / PO Box 8124 Perth BC WA 6849

T: +61 (0)8 9227 7500 **E:** mailbox@h**l**bwa.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (WA Partnership) is a member of HLB International, the global advisory and accounting network.

Independent Auditor's Report to the Members of Arthritis Foundation of W.A. Incorporated

REPORT ON THE AUDIT OF THE FINANCIAL REPORT

Opinion

We have audited the financial report of Arthritis Foundation of W.A. Incorporated ("the Foundation") which comprises the statement of financial position as at 31 December 2023, the statement of comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, and the declaration by the board of management.

In our opinion, the accompanying financial report of the Foundation has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (a) giving a true and fair view of the Foundation's financial position as at 31 December 2023 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Foundation in accordance with the auditor independence requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* ("the Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Report and Auditor's Report Thereon

The board of management is responsible for the other information. The other information comprises the information included in the Foundation's annual report for the year ended 31 December 2023, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

hlb.com.au

HLB Mann Judd (WA Partnership) ABN 22 193 232 714

Level 4, 130 Stirling Street, Perth WA 6000 / PO Box 8124 Perth BC WA 6849

T: +61 (0)8 9227 7500 **E:** mailbox@hlbwa.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (WA Partnership) is a member of HLB International, the global advisory and accounting network.

Responsibilities of the Board of Management for the Financial Report

The board of management is responsible for the preparation of the financial report that gives a true and fair view in accordance with the Australian Accounting Standards and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the board of management determines is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the board of management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of management either intends to liquidate the Foundation or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the board of management.
- Conclude on the appropriateness of the board of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the board of management with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

HLB Mann Judd

HLB Mann Judd
Chartered Accountants

Perth, Western Australia
12 April 2024



L Di Giallonardo
Partner

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 December 2023

	NOTE	2023 \$	2022 \$
OPERATIONAL ITEMS			
Revenue	3	3,140,352	3,342,620
<i>Expenses:</i>			
Branches and community support groups		(162,275)	(139,322)
Education		(826,735)	(676,673)
Administration		(183,746)	(197,501)
Health services		(1,066,095)	(945,879)
Fundraising and public relations		(749,133)	(743,163)
Research		(200,294)	(94,549)
(Deficit)/Surplus from operations	4	<u>(47,926)</u>	<u>545,533</u>
NON-OPERATIONAL ITEMS			
Net fair value gain on investment properties	11	-	30,000
Gain on sale of financial assets		15,803	-
Net fair value gain/(loss) on financial assets at fair value through profit or loss	9	881,145	(1,540,016)
Gain/(loss) from non-operational items		<u>896,948</u>	<u>(1,510,016)</u>
Net surplus/(deficit) before income tax expense		<u>849,022</u>	<u>(964,483)</u>
Income tax expense	1(b)	-	-
Surplus/(deficit) after income tax expense		<u>849,022</u>	<u>(964,483)</u>
Total other comprehensive income		-	-
Total comprehensive income/(deficit) for the year		<u>849,022</u>	<u>(964,483)</u>

The accompanying notes form part of these financial statements

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	NOTE	2023 \$	2022 \$
CURRENT ASSETS			
Cash and cash equivalents	5	292,047	1,025,575
Financial assets	6	2,441,310	2,452,260
Trade and other receivables	7	76,758	79,180
Other current assets	8	178,128	140,681
TOTAL CURRENT ASSETS		2,988,243	3,697,696
NON-CURRENT ASSETS			
Financial assets at fair value through profit or loss	9	12,934,913	11,679,891
Property, plant and equipment	10	1,431,254	1,215,174
Investment properties	11	580,000	580,000
Right-of-use asset	12	-	10,024
TOTAL NON-CURRENT ASSETS		14,946,167	13,485,089
TOTAL ASSETS		17,934,410	17,182,785
CURRENT LIABILITIES			
Trade and other payables	13	295,970	145,831
Contract liabilities	14	127,962	136,313
Provisions	15	432,384	550,155
Lease liabilities		-	10,480
TOTAL CURRENT LIABILITIES		856,316	842,779
NON-CURRENT LIABILITIES			
Provisions	15	-	110,934
TOTAL NON-CURRENT LIABILITIES		-	110,934
TOTAL LIABILITIES		856,316	953,713
NET ASSETS		17,078,094	16,229,072
EQUITY			
Accumulated funds			
Unrestricted funds		2,791,970	1,866,668
Restricted funds	16	6,889,523	6,965,803
Designated funds	17	7,396,601	7,396,601
TOTAL EQUITY		17,078,094	16,229,072

The accompanying notes form part of these financial statements

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2023

	Restricted Funds	Designated Funds	Unrestricted Funds	Total
	\$	\$	\$	\$
Balance at 1 January 2022	8,844,200	5,500,000	2,849,355	17,193,555
Deficit after income tax expense	-	-	(964,483)	(964,483)
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive deficit for the year	-	-	(964,483)	(964,483)
Transfers between equity categories	(1,878,397)	1,896,601	(18,204)	-
Balance at 31 December 2022	6,965,803	7,396,601	1,866,668	16,229,072
Balance at 1 January 2023	6,965,803	7,396,601	1,866,668	16,229,072
Surplus after income tax expense	-	-	849,022	849,022
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	849,022	849,022
Transfers between equity categories	(76,280)	-	76,280	-
Balance at 31 December 2023	6,889,523	7,396,601	2,791,970	17,078,094

The accompanying notes form part of these financial statements

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

STATEMENT OF CASH FLOWS

For the year ended 31 December 2023

	NOTE	2023 \$	2022 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from operations		2,609,387	2,679,388
Payments to suppliers and employees		(3,205,570)	(3,167,016)
Interest received		106,022	35,660
Dividends and trust distributions received		422,329	554,301
Interest paid		(218)	(839)
Net cash (used in)/provided by operating activities	18(a)	(68,050)	101,494
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments for plant and equipment		(307,874)	(41,787)
Payments for financial assets at fair value through profit or loss		(1,151,404)	(224,989)
Proceeds from sale of financial assets at fair value through profit or loss		793,330	135,104
Net cash (used in) investing activities		(665,948)	(131,672)
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of lease liabilities		(10,480)	(19,042)
Net cash (used in) financing activities		(10,480)	(19,042)
Net (decrease) in cash and cash equivalents		(744,478)	(49,220)
Cash and cash equivalents at the beginning of the financial year		3,477,835	3,527,055
Cash and cash equivalents at the end of the financial year	18(b)	2,733,357	3,477,835

The accompanying notes form part of these financial statements

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The financial statements cover the Arthritis Foundation of W.A. Incorporated (“the Foundation”) as an individual entity. The financial statements are presented in Australian dollars, which is the Foundation’s functional and presentation currency. The Foundation is a not-for-profit entity that is incorporated in Western Australia under the *Associations Incorporation Act 2015*.

The financial statements were authorised for issue on 12 April 2024.

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

New, revised or amending Accounting Standards and Interpretations adopted

The Foundation has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

The Board has also reviewed all of the new and revised Standards and Interpretations in issue not yet adopted for the year ended 31 December 2023 and determined that there is no material impact of the Standards and Interpretations in issue not yet adopted on the Foundation and, therefore, no change is necessary to accounting policies.

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB'), the *Associations Incorporation Act 2015*, the *Australian Charities and Not-for-profits Commission Act 2012* and the *Charitable Collections Act 1946 (WA)* and associated regulations, as appropriate for not-for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Foundation's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

(a) Revenue recognition

The Foundation recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the Foundation is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the Foundation: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Sales revenue

Events, fundraising and raffles are recognised when received or receivable.

Donations

Donations are recognised at the time the pledge is made. Except for when a donation gives rise to related amounts of a contribution by owners, lease liability, financial liability or a provision.

Grants

Grant revenue is recognised in profit or loss when the Foundation satisfies the performance obligations stated within the funding agreements.

If conditions are attached to the grant which must be satisfied before the Foundation is eligible to retain the contribution, the grant will be recognised in the statement of financial position as a liability until those conditions are satisfied.

Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Dividends

Dividend revenue is recognised when the right to receive a dividend has been received.

Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

Volunteer services

The Foundation has elected not to recognise volunteer services as either revenue or other form of contribution received. As such, any related consumption or capitalisation of such resources received is also not recognised.

(b) Income tax

The Foundation is exempt from income tax under the provisions of Section 50-5 of the Income Tax Assessment Act 1997 as a charitable institution and holds deductible gift recipient status.

(c) Allocation of expenses

The Foundation reports its expenditure on a functional basis and accordingly, classifies its expenditure to specific programme services which describe the Foundation's social service activities and supporting services. Additionally, there is an expense classification of Administration in respect of expenditure of an administrative and general nature that is incurred and is not identifiable with a single programme but is indispensable to the conduct of those activities and to the Foundation's existence.

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

(d) Fund accounting

On occasions the Foundation may receive resources restricted for particular purposes. To facilitate observance of these limitations, the financial statements list separately those funds which are restricted or designated and those funds which are unrestricted. Restricted funds are those funds presently available for use, but expendable only for operating purposes specified by the donor or by statute. When the Board specifies a purpose for the expenditure of funds, where none has been stated by the original donor, such funds are classified as designated funds.

Unrestricted funds are those funds presently available for use by the Foundation at the discretion of the Board.

(e) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Foundation's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Foundation's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

(f) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

(g) Trade and other receivables

Other receivables are recognised at amortised cost, less any provision for expected credit loss.

(h) Property, plant and equipment

Buildings and plant and equipment are measured on the cost basis less depreciation, and any accumulated impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a reducing balance method for plant and equipment and straight-line method for land and building over their expected useful lives. The depreciation rates used for each class of asset are as follows:

	Depreciation rate
Plant and equipment	7.5–30%
Building	2.0%

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

(h) Property, plant and equipment (Cont.)

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Foundation. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

(i) Investment properties

Investment properties principally comprise of freehold land and buildings held for long-term rental and capital appreciation that are not occupied by the Foundation. Investment properties are initially recognised at cost, including transaction costs, and are subsequently remeasured annually at fair value. Movements in fair value are recognised directly to profit or loss.

Investment properties are derecognised when disposed of or when there is no future economic benefit expected.

Transfers to and from investment properties to property, plant and equipment are determined by a change in use of owner-occupation. The fair value on the date of change of use from investment properties to property, plant and equipment are used as deemed cost for the subsequent accounting. The existing carrying amount of property, plant and equipment is used for the subsequent accounting cost of investment properties on the date of change of use.

Investment properties also include properties under construction for future use as investment properties. These are carried at fair value, or at cost where fair value cannot be reliably determined and the construction is incomplete.

(j) Right of use asset

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Foundation expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Foundation has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

(k) Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

(l) Trade and other payables

These amounts represent liabilities for goods and services provided to the Foundation prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(m) Contract liabilities

Contract liabilities represent the Foundation's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Foundation recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Foundation has transferred the goods or services to the customer.

(n) Provisions

Provisions are recognised when the Foundation has a present (legal or constructive) obligation as a result of a past event, it is probable the Foundation will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

(o) Employee benefits

Provision is made for the Foundation's liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs. Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits.

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

(p) Lease Liability

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Foundation's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

(q) Financial Instruments

Financial assets

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless, an accounting mismatch is being avoided.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the Foundation has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

Financial assets at fair value through profit or loss

Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii) designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss.

Impairment of financial assets

The Foundation recognises a loss allowance for expected credit losses on financial assets which are either measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance depends upon the Foundation's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain.

Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

(q) Financial Instruments (Cont.)

increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.

(r) Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

(s) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

2. CRITICAL ACCOUNTING JUDGEMENTS ESTIMATES AND ASSUMPTIONS

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements estimate and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

2. CRITICAL ACCOUNTING JUDGEMENTS ESTIMATES AND ASSUMPTIONS (Cont.)

Impairment

The Foundation assesses impairment at each reporting date by evaluating conditions specific to the Foundation that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. Value-in-use calculations performed in assessing recoverable amounts incorporate a number of key estimates.

Revenue from contracts with customers

When recognising revenue in relation to contracts with customers, involves a degree of judgement to be applied when determining whether a promise is 'sufficiently specific' or not. All conditions specified in the arrangements regarding the promised goods and services need to be considered (both explicit and implicit) including those regarding: The nature or type of goods or services, the cost or value of goods or services, the quantity of goods or services, and the period of time over which the goods or services must be transferred. Each promise is assessed separately to determine if it is 'sufficiently specific' enough to qualify as a performance obligation.

	2023	2022
	\$	\$
3. REVENUE (*)		
Charitable support fundraising (**)	1,348,839	1,615,180
Fee for services	396,812	369,072
Grants	927,122	723,404
Interest income	106,023	35,660
Dividend income	336,662	554,301
Rental income	14,061	15,619
Other revenue	10,833	29,384
	3,140,352	3,342,620

* Geographical region where revenue is sourced: Australia.

** Amount includes bingo income of \$442,950 (2022: \$370,133).

4. SURPLUS/DEFICIT FROM OPERATIONAL ITEMS

Surplus/deficit from operational items includes the following specific expenses:

Depreciation and amortisation

Buildings and work in progress	42,692	56,328
Plant and equipment	47,471	55,584
Right-of-use asset	10,024	18,670
	100,187	130,582

Superannuation

Defined contributions superannuation expense	144,258	127,596
--	----------------	----------------

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

	2023	2022
	\$	\$
5. CASH AND CASH EQUIVALENTS		
Cash on hand	630	630
Cash at bank	203,766	834,881
Cash on deposit	87,651	190,064
	292,047	1,025,575
6. FINANCIAL ASSETS		
<u>Current</u>		
Fixed maturity deposits	2,441,310	2,452,260
7. TRADE AND OTHER RECEIVABLES		
Trade receivables	76,758	78,480
Other receivables	-	700
	76,758	79,180
8. OTHER CURRENT ASSETS		
Accrued interest	16,707	12,784
Franking credits due	58,641	64,556
Dividends due	20,400	13,374
Prepayments	53,840	42,323
GST receivable	28,540	7,644
	178,128	140,681
9. FINANCIAL ASSETS - AT FAIR VALUE THROUGH PROFIT OR LOSS		
<u>Non-current</u>		
Shares in listed companies (Level 1)	4,190,997	3,068,452
Managed funds (Level 1)	5,121,639	4,912,882
Units in unlisted investment unit trusts (Level 2)	3,622,277	3,698,557
	12,934,913	11,679,891

Reconciliation of the opening and closing carrying values of the current and previous financial years are set out below:

2023

	Shares in listed companies	Managed funds	Units in unlisted investment unit trusts	Total
	\$	\$	\$	\$
Opening carrying value	3,068,452	4,912,882	3,698,557	11,679,891
Additions	921,404	230,000	85,668	1,237,072
Disposal	(101,515)	(447,483)	-	(548,998)
Gain/(loss) on sale	(2,326)	18,129	-	15,803
Revaluation gain recognised in profit or loss	304,982	408,111	168,052	881,145
Other adjustment**	-	-	(330,000)	(330,000)
Closing carrying value	4,190,997	5,121,639	3,622,277	12,934,913

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

9. FINANCIAL ASSETS - AT FAIR VALUE THROUGH PROFIT OR LOSS (Cont.)

2022

	Shares in listed companies	Managed funds	Units in unlisted investment unit trusts	Total
	\$	\$	\$	\$
Opening carrying value	3,441,208	5,658,461	4,030,353	13,130,022
Additions	224,989	-	-	224,989
Disposal	(135,104)	-	-	(135,104)
Revaluation (loss) recognised in profit or loss	(268,143)	(940,077)	(331,796)	(1,540,016)
Other adjustment*	(194,498)	194,498	-	-
Closing carrying value	<u>3,068,452</u>	<u>4,912,882</u>	<u>3,698,557</u>	<u>11,679,891</u>

*Represents correction of allocation between managed funds and shares in listed entities.

**Represents withdrawal of cash from investment fund to the Foundation's cash account.

Risk management

Balances as at 31 December 2023 include a portfolio of securities listed on the Australian Securities Exchange and units in unlisted unit trusts, the latter managed by professional investment managers. These investments are spread across a range of various industrial and geographical sectors in accordance with the Foundation's investment policy to reduce exposure to market price risk.

	2023 \$	2022 \$
10. PROPERTY, PLANT AND EQUIPMENT		
Buildings		
Lemnos Street, Shenton Park		
Cost	2,380,357	2,380,357
Accumulated depreciation	(1,339,837)	(1,281,246)
	<u>1,040,520</u>	<u>1,099,111</u>
Plant and equipment		
Cost	307,525	322,393
Accumulated depreciation	(252,369)	(234,035)
	<u>55,156</u>	<u>88,358</u>
Work in progress	335,578	27,705
Total property, plant and equipment	<u>1,431,254</u>	<u>1,215,174</u>

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

Reconciliation of the opening and closing carrying values at the opening and closing of the current and previous financial years are set out below:

2023

	Buildings and work in progress	Plant and Equipment	Total
	\$	\$	\$
Opening carrying value	1,126,816	88,358	1,215,174
Additions	307,874	-	307,874
Disposal	-	(14,869)	(14,869)
Depreciation write back on disposal	-	13,238	13,238
Depreciation expense	<u>(58,590)</u>	<u>(31,572)</u>	<u>(90,162)</u>
Closing carrying value	<u>1,376,100</u>	<u>55,155</u>	<u>1,431,255</u>

2022

	Buildings and work in progress	Plant and Equipment	Total
	\$	\$	\$
Opening carrying value	1,163,250	122,049	1,285,299
Additions	19,894	21,893	41,787
Depreciation expense	<u>(56,328)</u>	<u>(55,584)</u>	<u>(111,912)</u>
Closing carrying value	<u>1,126,816</u>	<u>88,358</u>	<u>1,215,174</u>

The Foundation's buildings and improvements are situated on Crown Land, and title was previously held through a Reserve and vested in the name of the Foundation, over which there was a reservation, which designated that the land must be used for the purpose of an "Arthritis Centre". During the year ended 31 December 2001, the Foundation applied for and was granted a Crown Grant in Trust title whereby the Foundation must continue to use the building and improvements as before, for the purpose of an "Arthritis Centre".

	2023	2022
	\$	\$
11. INVESTMENT PROPERTIES		
Land and buildings	<u>580,000</u>	<u>580,000</u>

Reconciliation of the carrying values at the opening and closing of the current and previous financial years are set out below:

Opening carrying value	580,000	550,000
Disposals	-	-
Revaluation gain recognised in profit or loss	-	30,000
Closing carrying value	<u>580,000</u>	<u>580,000</u>

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

	2023	2022
	\$	\$
12. RIGHT-OF-USE ASSET		
Motor vehicles		
Cost	-	64,655
Accumulated Amortisation	-	(54,631)
	-	10,024
	-	10,024
The Foundation leases a motor vehicle under an agreement of more than one year but less than two years.		
13. TRADE AND OTHER PAYABLES		
Trade creditors	222,330	40,807
Other accruals and payables	73,640	105,024
	295,970	145,831
	295,970	145,831
14. CONTRACT LIABILITIES		
Contract liabilities	127,962	136,313
	127,962	136,313
15. PROVISIONS		
Current		
Employee benefits	198,499	159,771
Funding for research	233,885	390,384
	432,384	550,155
Non-current		
Employee benefits	-	25,895
Funding for research	-	85,039
	-	110,934
	-	110,934
Total provisions	432,384	661,089
	432,384	661,089

Employee benefits

The provisions represent the present value of employee annual leave and long service leave.

Funding for research

The provision relates to constructive obligations the Foundation has created to provide funding for the purposes of research. This funding relates to the Foundations total cost of supporting the Professor in Rheumatology and a Research Officer at the University of WA for a period of five years until 30 June 2024.

	Notes	2023	2022
		\$	\$
16. RESTRICTED FUNDS			
<i>Funds restricted by Donors</i>	1(d)		
Education		293,000	293,000
Research		1,975,150	1,975,150
Statutory (Lemnos Street Building)		969,096	969,096
Charitable trusts		3,622,277	3,698,557
Lupus Group		30,000	30,000
		6,889,523	6,965,803
		6,889,523	6,965,803

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

	Notes	2023	2022
		\$	\$
17. DESIGNATED FUNDS			
<i>Funds restricted by Board</i>	1(d)		
Building maintenance		1,500,000	1,500,000
Research		2,000,000	2,000,000
Capital Resource Centre		2,000,000	2,000,000
Chair Rheumatology & Musculoskeletal Medicine		1,896,601	1,896,601
		7,396,601	7,396,601

18. NOTES TO THE STATEMENT OF CASH FLOWS

(a) Reconciliation of net cash provided by operating activities to net surplus/(deficit):

Surplus/(deficit) after income tax expense for the year	849,022	(964,483)
Adjustments for:		
Depreciation and amortisation expense	100,187	130,582
Net fair value gain on investment properties	-	(30,000)
Net fair value (gain)/loss on financial assets at fair value through profit or loss	(881,145)	1,540,016
Profit on disposal of financial assets	(15,803)	-
Loss on disposal of property, plant & equipment	1,630	-
Movements in assets and liabilities:		
Trade and other receivables	2,422	(35,942)
Other current assets	(37,447)	(39,472)
Trade and other payables	141,789	(372,493)
Contract liabilities	(117,771)	-
Provisions	(110,934)	(126,714)
	(68,050)	101,494

(b) Reconciliation of cash

Cash at the end of the financial year, as shown in the statement of cash flows is reconciled to items in the statement of financial position as follows:

	2023	2022
	\$	\$
Cash and cash equivalents (Note 5)	292,047	1,025,575
Fixed maturity deposits (Note 6)	2,441,310	2,452,260
	2,733,357	3,477,835

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

19. FINANCIAL INSTRUMENTS

Financial risk management

The main risks arising from the Foundation's financial instruments are interest rate risk, liquidity risk, credit risk and market price risk. The Foundation does not hold financial instruments denominated in foreign currencies and does not use derivative instruments to manage risks associated with its financial instruments.

The Foundation's policies for managing each of these risks are summarised below. The policies are subject to Board approval and are reviewed regularly.

(a) Interest rate risk

The Foundation is not exposed to any significant interest rate risk.

(b) Liquidity risk

The Foundation manages liquidity risk by monitoring forecast cash flows and ensuring that adequate liquid funds are maintained.

When necessary, cash for unforeseen events may be sourced from liquidation of available-for-sale financial investments. It is Foundation investment policy that 50% of total investment must be liquefiable within 14 days.

Remaining contractual maturities

The following tables detail the Foundation's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

2023

	Weighted average interest rate %	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
Non-derivative						
<i>Non- interest bearing</i>						
Trade and other payables	-	295,970	-	-	-	-
		295,970	-	-	-	-

2022

	Weighted average interest rate %	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
Non-derivative						
<i>Non- interest bearing</i>						
Trade and other payables	-	145,831	-	-	-	-
		145,831	-	-	-	-

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

19. FINANCIAL INSTRUMENTS (Cont.)

(c) Credit risk

The Foundation is exposed to credit risk in respect of funds deposited with banks and other financial institutions.

Funds are deposited only with those banks and financial institutions approved by the Board. Such approval is only given in respect of banks that hold an A1 rating from Standard and Poor's.

At the reporting date, the Foundation does not have any material credit risk exposures to any single bank or financial institution.

(d) Market price risk

Market price risk is the risk that the Foundation's operations will be adversely affected by a significant adverse fluctuation on the value of its financial assets at fair value through profit or loss. The Foundation has engaged a licensed investment advisor to advise on the management of its investment portfolio. The Board has approved risk and return parameters for investment in its financial assets at fair value through profit or loss and receives reports from management and its licensed investment advisor on a monthly basis regarding the performance of the investment portfolio.

Market price sensitivity

At 31 December 2023, if market prices had changed by +/- 15%, with all other variables held constant, the net assets for the year and equity would have been \$1,940,237 higher/lower (2022: \$1,751,984 higher/lower).

(e) Fair value of financial instruments

Unless stated otherwise the carrying amounts of financial instruments reflect their fair value.

20. KEY MANAGEMENT PERSONNEL DISCLOSURES

Compensation

The aggregate compensation made to members of the Board of Management and other key management personnel of the Foundation is set out below:

	2023	2022
	\$	\$
Short-term employee benefits	260,747	304,852
Post-employment benefits	44,699	40,251
	<u>305,446</u>	<u>345,103</u>

21. REMUNERATION OF AUDITORS

During the financial year the following fees were paid or payable for services provided by HLB Mann Judd (WA Partnership), the auditor of the Foundation:

Audit of the financial statements	<u>14,000</u>	<u>15,600</u>
-----------------------------------	---------------	---------------

ARTHRITIS FOUNDATION OF W.A. INCORPORATED

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

22. RELATED PARTY INFORMATION

Members of the board of management

The names of the members of the Board of Management, who serve in a voluntary capacity and are not remunerated, in office during any part of the year were:

Dr Jack Edelman – President
Dr Irene Dagmar Froyland – Vice President
Dr Silvia Caratti – Honorary Treasurer
Dr Charles Inderjeeth – Member
Mr Bradley Gordon – Member
Ms Anita Clayton – Member
Dr Joe Kosterich – Member
Mr Bill Cox – Member

Key management personnel

Disclosures relating to key management personnel are set out in Note 20.

Transactions with related parties

There were no transactions with related parties during the current and previous financial year.

Receivable from and payable to related parties

There were no trade receivables from or trade payables to related parties at the current and previous reporting dates.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting dates.

23. BEQUESTS AND LEGACIES NOT YET RECORDABLE

The Foundation is the beneficiary of certain bequests and legacies and a donation, under various wills of deceased benefactors and an agreement respectively, the total realisable amount of which is not presently determinable. Such amounts will be recorded when clear title is established, and the proceeds are measurable.

24. CONTINGENT LIABILITIES

The Foundation has no contingent liabilities at 31 December 2023.

25. EVENTS SUBSEQUENT TO REPORTING DATE

No other matter or circumstance has arisen since 31 December 2023 that has significantly affected, or may significantly affect the Foundation's operations, the results of those operations, or the Foundation's state of affairs in future financial years.

26. FOUNDATION DETAILS

The principal place of business of the Foundation is:

Wyllie Arthritis Centre
17 Lemnos Street
Shenton Park WA 6008



Wyllie Arthritis Centre

17 Lemnos Street, Shenton Park WA 6008
Post Office Box 34, Wembley WA 6913

Telephone: 1800 011 041

Email: general@arthritiswa.org.au

Website: www.arthritiswa.org.au

ABN: 43 390 598 024

